Innovative Therapeutics Oblique Therapeutics specializes in the development of antibody therapies for severe diseases with unmet medical needs, presenting opportunities to collaborate with pharmaceutical companies seeking novel biologics, especially those focused on pain management.

Strategic Partnerships Recent collaborations with AAX Biotech and Targovax highlight Oblique’s capability to forge partnerships in antibody enhancement and oncolytic virus delivery, opening avenues for joint development initiatives or licensing opportunities.

Growth Potential Though currently small with revenue under $1 million, Oblique has attracted over $2.5 million in funding and partnered with mid-sized pharma, indicating strong investor confidence and room for scale, making it an attractive target for strategic investment or acquisition.

Technology Platform Oblique’s proprietary Abiprot® antibody platform enables access to challenging epitopes, offering potential for co-development with biotech firms interested in cutting-edge antibody discovery or proprietary antibody platforms.

Unmet Market Needs Focused on pain-related conditions and intracellular targets, Oblique’s research aligns with market demand for innovative therapies addressing large unmet needs, creating opportunities for sales of early-stage therapeutics or partnership in late-stage clinical development.